AR247395A1 - Procedimiento para preparar compuestos que poseen actividad antiviral - Google Patents
Procedimiento para preparar compuestos que poseen actividad antiviralInfo
- Publication number
- AR247395A1 AR247395A1 AR89313534A AR31353489A AR247395A1 AR 247395 A1 AR247395 A1 AR 247395A1 AR 89313534 A AR89313534 A AR 89313534A AR 31353489 A AR31353489 A AR 31353489A AR 247395 A1 AR247395 A1 AR 247395A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- iodine
- chlorine
- react
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
- C07C35/04—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a three or four-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
PREPARACION DE COMPUESTOS CON ACTIVIDAD ANTIVIRAL, DE FORMULA 1 Y SUS SALES FARMACEUTICAMENTE ACEPTABLES EN DONDE R1 ES (A), DONDE R3 ES FLUOR, CLORO, BROMO, YODO, HIDROGENO, METILO, ETILO, N-PROPILO, 2-FLUOROETILO, 2- CLOROETILO, O-HC=CR4H, EN DONDE R4 ES CLORO, BROMO, YODO, HIDROGENO O METILO, QUE COMPRENDE A) CUANDO R1 ES(B), HACER REACCIONAR UN COMPUESTO DE FORMULA (2), SIENDO P (C),Y X ES EL GRUPO SALIENTE (D), CON UN COMPUESTO DE FORMULA (E), SEGUIDO DE TRATAMIENTO CON METOXIDO DE SODIO EN METANOL, Y CON HCE, B) CUANDO R1 ES (F), EN DONDE R3 ES HIDROGENO, METILO, ETILO, N- PROPILO, FLUOR, 2-CLOROETILO O 2-FENOCOETILO, HACER REACCIONAR UN COMPUESTO DE FORMULA (2) CON UM COMPUESTO DE FORMULA (G), SEGUIDO DE TRATAMIENTO CON METOXIDO DE SODIO EN METANOL,C) CUANDO R1 ES(H) HACER REACCIONAR UN COMPUESTO DE FORMULA (I) CON UNA FUENTE DE BROMO; D) CUANDO R1 ES (J), Y R3 ES YODO, CLORO, O BROMO, HACER REACCIONAR UN COMPUESTO DE FORMULA (K), CON UNA FUENTE DE YODO,CLORO Y BROMO; Y E) CU ANDO R1 ES (L), HACER REACCIONAR UN COMPUESTO DE FORMULA (M) CON ACETATO DE PALADIO, PARA DAR EL INTERMEDIARIO (N) EL CUAL SE CONVIERTE, CON N- BROMOSUCCINIMIDA, O EL CORRESPONDIENTE DE CLORO O YODO, PARA DAR EL COMPUESTO FINAL DESEADO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17537688A | 1988-03-30 | 1988-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR247395A1 true AR247395A1 (es) | 1994-12-29 |
Family
ID=22640016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AR89313534A AR247395A1 (es) | 1988-03-30 | 1989-03-29 | Procedimiento para preparar compuestos que poseen actividad antiviral |
Country Status (31)
Country | Link |
---|---|
US (1) | US5723609A (es) |
EP (1) | EP0335355B1 (es) |
JP (1) | JP2694999B2 (es) |
KR (1) | KR970009223B1 (es) |
CN (1) | CN1031054C (es) |
AR (1) | AR247395A1 (es) |
AT (1) | ATE158797T1 (es) |
AU (2) | AU616494B2 (es) |
BR (1) | BR1100660A (es) |
CA (1) | CA1341201C (es) |
CZ (1) | CZ278493B6 (es) |
DD (1) | DD280325A5 (es) |
DE (1) | DE68928353T2 (es) |
DK (1) | DK170749B1 (es) |
EG (1) | EG18734A (es) |
ES (1) | ES2109218T3 (es) |
FI (1) | FI96420C (es) |
GR (1) | GR3025693T3 (es) |
HU (1) | HU203734B (es) |
IE (1) | IE81079B1 (es) |
IL (1) | IL89796A (es) |
MX (1) | MX15464A (es) |
NO (1) | NO168423C (es) |
NZ (1) | NZ228490A (es) |
PH (1) | PH26562A (es) |
PL (1) | PL158539B1 (es) |
PT (1) | PT90159B (es) |
RU (2) | RU2041213C1 (es) |
SK (1) | SK278165B6 (es) |
YU (1) | YU63789A (es) |
ZA (1) | ZA892185B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597824A (en) * | 1987-11-03 | 1997-01-28 | Abbott Laboratories | Analogs of oxetanyl purines and pyrimidines |
JP2577640B2 (ja) * | 1988-09-09 | 1997-02-05 | 日本化薬株式会社 | 新規なシクロブタン誘導体 |
AU622926B2 (en) * | 1988-09-09 | 1992-04-30 | Nippon Kayaku Kabushiki Kaisha | Pyrimidine or purine cyclobutane derivatives |
US5153352A (en) * | 1988-10-25 | 1992-10-06 | Bristol-Myers Squibb Company | Process for preparation of intermediates of carbocyclic nucleoside analogs |
IL92096A0 (en) | 1988-10-25 | 1990-07-12 | Abbott Lab | Carboxylic nucleoside analogs |
US5246931A (en) * | 1988-10-25 | 1993-09-21 | Bristol-Myers Squibb Company | Carbocyclic nucleoside analogs |
US5164520A (en) * | 1989-04-24 | 1992-11-17 | E. R. Squibb & Sons, Inc. | Intermediates for purinyl and pyrimidinyl tetrahydrofurans |
US5145960A (en) * | 1989-04-24 | 1992-09-08 | E. R. Squibb & Sons, Inc. | Pyrimidinyl tetrahydrofurans |
US5059690A (en) * | 1990-03-01 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Purinyl tetrahydrofurans |
NZ232993A (en) * | 1989-04-24 | 1992-10-28 | Squibb & Sons Inc | Purinyl and pyrimidinyl tetrahydrofurans |
JPH03173896A (ja) * | 1989-09-08 | 1991-07-29 | Nippon Kayaku Co Ltd | 新規オキセタノシン誘導体、その塩およびその用途 |
US5198583A (en) * | 1989-12-18 | 1993-03-30 | E. R. Squibb & Sons, Inc. | Optically active cyclobutane nucleoside and intermediates, therefor |
US5256806A (en) * | 1989-12-18 | 1993-10-26 | E. R. Squibb & Sons, Inc. | Intermediates for the preparation of optically active cyclobutane nucleoside |
US5064961A (en) * | 1989-12-18 | 1991-11-12 | E. R. Squibb & Sons, Inc. | Process for preparing an optically active cyclobutane nucleoside |
US5691307A (en) * | 1990-03-13 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | O6 -substituted guanine compositions and methods for depleting O6 |
US5352669A (en) * | 1990-03-13 | 1994-10-04 | The Of The United States Of America As Represented By The Department Of Health And Human Services | O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity |
US5235052A (en) * | 1990-04-16 | 1993-08-10 | Bristol-Myers Squibb Company | Process for preparing substituted cyclobutane purines |
JPH0421682A (ja) * | 1990-05-11 | 1992-01-24 | Asahi Chem Ind Co Ltd | 2―フルオロネプラノシンaおよびその製造法 |
US5324730A (en) * | 1990-05-24 | 1994-06-28 | Nippon Kayaku Kabushiki Kaisha | Phenoxyphosphoryloxymethyl cyclobutyl purines |
US5344962A (en) * | 1990-05-24 | 1994-09-06 | E. R. Squibb & Sons, Inc. | Intermediates in the synthesis of an optically active cyclobutane nucleoside |
CA2042931A1 (en) * | 1990-05-24 | 1991-11-25 | Robert Zahler | Fluorinated bis (hydroxymethyl) cyclobutyl purines and pyrimidines |
IE72143B1 (en) * | 1990-05-24 | 1997-03-26 | Squibb & Sons Inc | Process for preparing an optically active cyclobutanone an intermediate in the synthesis of an optically active cyclobutane nucleoside |
US5233076A (en) * | 1990-05-24 | 1993-08-03 | E. R. Squibb & Sons, Inc. | Process for preparing an optically active cyclobutanone, an intermediate in the synthesis of an optically active cyclobutane nucleoside |
EP0468352A3 (en) * | 1990-07-24 | 1992-07-15 | Nippon Kayaku Kabushiki Kaisha | Novel nucleic acid derivatives |
CA2052315A1 (en) * | 1990-10-09 | 1992-04-10 | Masashi Nagai | Cyclobutane derivatives |
USH1142H (en) | 1990-11-05 | 1993-02-02 | Optically active cyclobutyl pyrimidine | |
US5185463A (en) * | 1991-10-02 | 1993-02-09 | E. R. Squibb & Sons, Inc. | Process for the preparation of an antiviral agent |
US5218142A (en) * | 1991-10-02 | 1993-06-08 | E. R. Squibb & Sons, Inc. | Process for the preparation of an antiviral agent |
US5233086A (en) * | 1991-10-02 | 1993-08-03 | E. R. Squibb & Sons, Inc. | Intermediates for the preparation of an antiviral agent |
US5237096A (en) * | 1991-10-02 | 1993-08-17 | E. R. Squibb & Sons, Inc. | Process for the preparation of an antiviral agent |
US5237095A (en) * | 1991-10-02 | 1993-08-17 | E. R. Squibb & Sons, Inc. | Process for the preparation of an antiviral agent |
US5525726A (en) * | 1991-10-02 | 1996-06-11 | E. R. Squibb & Sons, Inc. | Process for the preparation of an antiviral agent |
DE4142568A1 (de) * | 1991-12-21 | 1993-06-24 | Basf Ag | Verfahren zur herstellung von 2,4,5-triamino-6-halogenopyrimidinen und 2-amino-6-halogenopurinen |
EP0554025A3 (en) * | 1992-01-27 | 1993-11-18 | Squibb & Sons Inc | Fluorinated cyclobutyl purines and pyrimidines |
US5412134A (en) * | 1992-05-26 | 1995-05-02 | E. R. Squibb & Sons, Inc. | Process for preparing diprotected 2,3-hydroxymethyl cyclobutanol |
GB9220585D0 (en) * | 1992-09-30 | 1992-11-11 | Smithkline Beecham Plc | Pharmaceuticals |
US5525606A (en) | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
EP0780126A1 (en) * | 1994-09-06 | 1997-06-25 | Nippon Kayaku Kabushiki Kaisha | Ointment |
IL117574A0 (en) * | 1995-04-03 | 1996-07-23 | Bristol Myers Squibb Co | Processes for the preparation of cyclobutanone derivatives |
WO1998052930A1 (fr) * | 1997-05-20 | 1998-11-26 | Nippon Kayaku Kabushiki Kaisha | Nouveaux derives de cyclobutane et leur procede de production |
US6060458A (en) * | 1998-02-13 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use |
KR101358626B1 (ko) * | 2008-11-27 | 2014-02-04 | 고쿠리츠다이가쿠호우징 카가와다이가쿠 | 시클로부틸 푸린 유도체, 혈관신생 촉진제, 관강 형성 촉진제, 신경세포 성장 촉진제 및 의약품 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4177348A (en) * | 1977-12-13 | 1979-12-04 | United States Government | Carbocyclic analogs of cytosine nucleosides |
US4232154A (en) * | 1977-12-13 | 1980-11-04 | United States Of America | Carbocyclic analogs of cytosine nucleosides exhibiting antiviral and antineoplasticactivity |
US4617304A (en) * | 1984-04-10 | 1986-10-14 | Merck & Co., Inc. | Purine derivatives |
EP0184473A1 (en) * | 1984-10-26 | 1986-06-11 | Merck & Co. Inc. | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives |
US4801710A (en) * | 1984-10-26 | 1989-01-31 | Merck & Co., Inc. | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives |
US4743689A (en) * | 1984-11-20 | 1988-05-10 | Nippon Kayaku Kabushiki Kaisha | Antibiotic derivative of adenine |
IN164556B (es) * | 1986-03-06 | 1989-04-08 | Takeda Chemical Industries Ltd | |
JPS62208295A (ja) * | 1986-03-07 | 1987-09-12 | Nippon Kayaku Co Ltd | ヒポキサンチン塩基を有する新規化合物およびその製造法 |
US4782062A (en) * | 1987-05-11 | 1988-11-01 | Merck & Co., Inc. | 9-(2-hydroxymethyl)cycloalkylmethyl) guanines |
US4855466A (en) * | 1987-12-28 | 1989-08-08 | E. R. Squibb & Sons, Inc. | Purinyl cyclobutanes |
AU622926B2 (en) * | 1988-09-09 | 1992-04-30 | Nippon Kayaku Kabushiki Kaisha | Pyrimidine or purine cyclobutane derivatives |
IL92096A0 (en) * | 1988-10-25 | 1990-07-12 | Abbott Lab | Carboxylic nucleoside analogs |
AU4378589A (en) * | 1988-10-25 | 1990-05-03 | Bristol-Myers Squibb Company | Carbocyclic nucleoside analogs |
US4918075A (en) * | 1988-12-20 | 1990-04-17 | E. R. Squibb & Sons, Inc. | Purinyl and pyrimidinyl cyclobutanes and their use as antiviral agents |
US5064961A (en) * | 1989-12-18 | 1991-11-12 | E. R. Squibb & Sons, Inc. | Process for preparing an optically active cyclobutane nucleoside |
-
1989
- 1989-03-13 US US07/322,375 patent/US5723609A/en not_active Expired - Fee Related
- 1989-03-22 ZA ZA892185A patent/ZA892185B/xx unknown
- 1989-03-28 CA CA000594809A patent/CA1341201C/en not_active Expired - Fee Related
- 1989-03-28 YU YU00637/89A patent/YU63789A/xx unknown
- 1989-03-29 RU SU894613846A patent/RU2041213C1/ru active
- 1989-03-29 CZ CS891934A patent/CZ278493B6/cs not_active IP Right Cessation
- 1989-03-29 NZ NZ228490A patent/NZ228490A/en unknown
- 1989-03-29 SK SK1934-89A patent/SK278165B6/sk unknown
- 1989-03-29 ES ES89105500T patent/ES2109218T3/es not_active Expired - Lifetime
- 1989-03-29 AR AR89313534A patent/AR247395A1/es active
- 1989-03-29 IL IL89796A patent/IL89796A/xx not_active IP Right Cessation
- 1989-03-29 EP EP89105500A patent/EP0335355B1/en not_active Expired - Lifetime
- 1989-03-29 DE DE68928353T patent/DE68928353T2/de not_active Expired - Fee Related
- 1989-03-29 AT AT89105500T patent/ATE158797T1/de not_active IP Right Cessation
- 1989-03-29 PH PH38389A patent/PH26562A/en unknown
- 1989-03-29 NO NO891322A patent/NO168423C/no not_active IP Right Cessation
- 1989-03-29 HU HU891581A patent/HU203734B/hu not_active IP Right Cessation
- 1989-03-29 KR KR1019890003979A patent/KR970009223B1/ko not_active IP Right Cessation
- 1989-03-29 FI FI891492A patent/FI96420C/fi not_active IP Right Cessation
- 1989-03-29 DK DK151889A patent/DK170749B1/da not_active IP Right Cessation
- 1989-03-29 IE IE96989A patent/IE81079B1/en not_active IP Right Cessation
- 1989-03-30 PL PL1989278545A patent/PL158539B1/pl unknown
- 1989-03-30 AU AU32276/89A patent/AU616494B2/en not_active Ceased
- 1989-03-30 EG EG16389A patent/EG18734A/xx active
- 1989-03-30 DD DD89327077A patent/DD280325A5/de unknown
- 1989-03-30 PT PT90159A patent/PT90159B/pt active IP Right Grant
- 1989-03-30 MX MX1546489A patent/MX15464A/es unknown
- 1989-03-30 CN CN89101971A patent/CN1031054C/zh not_active Expired - Fee Related
- 1989-03-30 JP JP1080214A patent/JP2694999B2/ja not_active Expired - Fee Related
-
1991
- 1991-08-05 AU AU81625/91A patent/AU630570B2/en not_active Ceased
-
1992
- 1992-03-10 RU SU925011117A patent/RU2055076C1/ru not_active IP Right Cessation
-
1997
- 1997-05-07 BR BR1100660-9A patent/BR1100660A/pt active IP Right Grant
- 1997-12-17 GR GR970403344T patent/GR3025693T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR247395A1 (es) | Procedimiento para preparar compuestos que poseen actividad antiviral | |
AU2286383A (en) | Microbicidal compositions of 1-cyclopropyl-1,4-di-hydro- 4-oxo-3-quinolinecarboxylic acid derivatives | |
ATE48945T1 (de) | Antivirale zusammensetzungen. | |
MX9304140A (es) | Sal de purina, proceso para su preparacion y proceso para preparar un agente antiviral mediante la reaccion de dicha sal. | |
JPS52153977A (en) | Synthesis of 5-fluorouracil and its derivatives | |
JPS5311948A (en) | Stabilized halogen-containing | |
JPS5432465A (en) | Preparation of 4-methyloxazole | |
JPS52285A (en) | Preparation of n1 *22tetrahydrofuryl**55fluorouracil | |
AR245722A1 (es) | Procedimiento para preparar un derivado 23-desoxi-27-halo de compuestos ll-f28249 y composicion para controlar insectos de las plantas excluyendo su aplicacion en animales y el hombre. | |
JPS52143285A (en) | Stabilization of cholesterol-oxydase | |
JPS5289680A (en) | Preparation of 1-(2-tetrahydrofuryl)-5-flurouracil | |
JPS5328123A (en) | Zinc compounds | |
JPS5344531A (en) | Purification of p-aminophenol | |
JPS52102415A (en) | Stable solution of uracil derivatives | |
JPS5383995A (en) | Production of neutral anhydrous sodium sulfate | |
JPS51147831A (en) | Inclined face displacing mechanism through remote controlling | |
JPS5377042A (en) | Preparation of optically active organic thiophosphotic acid | |
JPS53111003A (en) | Preparation of squalane | |
JPS52118479A (en) | Synthesis of n1-(2-tetrahydrofuranyl)-5-fluorouracil | |
JPS5283386A (en) | Synthesis of n1-(2,-furanidyl)-5-fluorouracil | |
JPS539778A (en) | Preparation of 5-fluorouracil derivativds | |
JPS5344498A (en) | Production of sodium hydroxide-dihydrate | |
JPS52116483A (en) | Synthesis of pyrimidine nucleoside | |
JPS5283385A (en) | Synthesis of n1-(2,-furanidyl)-5-flurouracil | |
JPS5278886A (en) | Synthesis of 5-fluorouracil derivatives |